CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating Expenses:
Research and development	$ 1,109,332	$ 968,759	$ 3,343,248	$ 2,324,432
General and administrative	1,612,305	769,219	3,557,701	1,579,754
Loss from Operations	(2,721,637)	(1,737,978)	(6,900,949)	(3,904,186)
Other Income (Expense)
Changes in fair value of derivative liabilities	684,000	30,266,000	5,925,000	(28,485,585)
Foreign exchange gain	0	0	0	775
Grant income	0	0	231,200	0
Loss on debt settlement agreements	(65,325)	(24,697)	(135,640)	(24,697)
Other income	0	0	1,828	0
Net Income (Loss)	$ (2,102,962)	$ 28,503,325	$ (878,561)	$ (32,413,693)
Basic Net Income (Loss) per Share	$ (0.29)	$ 7.04	$ (0.14)	$ (10.61)
Diluted Net Income (Loss) per Share	$ (0.29)	$ 4.23	$ (0.54)	$ (10.61)
Weighted Average Number of Common Shares Outstanding, Basic	7,281,000	4,048,750	6,370,000	3,054,297
Weighted Average Number of Common Shares Outstanding, diluted	7,281,000	6,745,416	6,935,000	3,054,297